Rate My Professor Nagy Habib

A pioneering translational researcher, Professor Habib led the first clinical trial of plasmid and adenovirus for liver cancer treatment and advanced hydrodynamic gene delivery with plasmid therapy. He served as principal investigator for world-first trials using adult bone marrow-derived stem cells for liver insufficiency and CD34+ cells for stroke patients. His inventions include the Habib™ 4X radiofrequency device for bloodless liver resection, licensed to AngioDynamics and applied in over 70,000 patients worldwide, and the Habib™ EndoHPB catheter for palliation of pancreatic and biliary cancers, acquired by Boston Scientific and recipient of the Gold Edison Award for Medical Innovation in 2020; these stemmed from the Imperial spin-out EMcision Limited. Currently, he organizes Phase I/II trials for MTL-CEBPA small activating RNA (saRNA) therapy in liver cancer and cirrhosis (OUTREACH, TIMEPOINT, OUTREACH2 studies) and develops RNA aptamers for targeted siRNA delivery in pancreatic cancer. With more than 340 peer-reviewed publications, his contributions have profoundly influenced hepatobiliary surgery, oncology, and interventional therapies. Honors include election to the French Academy of Surgeons, the European Surgical Association, and selection as one of the top 10 surgeons in the UK by The Saturday Times Magazine.